10-Q: Kyverna Reports Q3 2025 Losses Amid Clinical Progress

Kyverna Therapeutics reports increased net losses for Q3 and nine months ended September 30, 2025, while advancing its lead cell therapy candidate KYV-101 in late-stage clinical trials for autoimmune diseases and securing new financing.

Summary

• Kyverna Therapeutics, a clinical-stage biopharmaceutical company, is developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101 in late-stage clinical development for neuroimmunology and rheumatology.
• The company reported a net loss of $36.8 million for the three months ended September 30, 2025, compared to $34.5 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $123.5 million, up from $90.0 million in the prior year period.
• Accumulated deficit reached $387.0 million as of September 30, 2025.
• Research and development expenses increased by 4% to $30.5 million for the three months ended September 30, 2025, and by 31% to $103.7 million for the nine months ended September 30, 2025, primarily due to accelerated enrollment in KYSA trials and strategic investment in CMO activities for KYV-101.
• General and administrative expenses decreased by 14% to $8.3 million for the three months ended September 30, 2025, but increased by 19% to $26.8 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and available-for-sale marketable securities totaled $171.1 million as of September 30, 2025.
• The company secured an initial $25.0 million funding under a new $150.0 million loan and security agreement with Oxford Finance in October 2025, extending its cash runway into 2027.
• Patient enrollment for the Phase 2 trial in Stiff Person Syndrome (SPS) was completed in Q2 2025, with top-line data expected in early 2026.
• The KYSA-6 Phase 2 trial in Myasthenia Gravis (MG) was amended into a registrational Phase 2/3 trial, with positive interim data presented in October 2025. Phase 3 enrollment is expected by the end of 2025.
• An Investigational New Drug (IND) application for KYV-102 is expected to be filed in Q4 2025.
• Material weaknesses in internal control over financial reporting were identified and remediation efforts are ongoing, though not yet fully concluded as of September 30, 2025.
• The company is a defendant in a shareholder class action and derivative complaints related to its IPO registration statement, alleging material misstatements or omissions.

Sentiment

Score: 4

Explanation: While there is positive clinical progress and new financing, the significant increase in net losses, substantial cash burn, and persistent material weaknesses in internal controls, coupled with ongoing litigation and industry-wide regulatory scrutiny on CAR T-cell therapies, indicate a challenging financial and operational environment. The new loan provides runway but also adds debt obligations and restrictions.

Positives

• Completed patient enrollment for the Phase 2 trial in Stiff Person Syndrome (SPS) during Q2 2025, with top-line data expected in early 2026.
• Presented positive interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in Myasthenia Gravis (MG) at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in October 2025.
• Received Regenerative Medicine Advanced Therapy (RMAT) designations and Orphan Drug Designations from the FDA for both SPS and MG, and Orphan Drug Designation from the European Medicines Association in MG.
• Secured a new non-dilutive term loan facility of up to $150.0 million with Oxford Finance in October 2025, with an initial draw of $25.0 million, extending the cash runway into 2027.
• Remediation efforts for identified material weaknesses in internal control over financial reporting are substantially designed and implemented, including hiring additional accounting and IT personnel.

Negatives

• Net loss increased to $36.8 million for the three months ended September 30, 2025, from $34.5 million in the prior year.
• Net loss for the nine months ended September 30, 2025, increased to $123.5 million from $90.0 million in the prior year.
• Accumulated deficit grew to $387.0 million as of September 30, 2025.
• Cash and cash equivalents and available-for-sale marketable securities decreased to $171.1 million as of September 30, 2025, from $285.4 million as of December 31, 2024.
• Interest income decreased significantly due to lower cash and investment balances.
• Material weaknesses in internal control over financial reporting persist as of September 30, 2025, indicating controls have not operated for a sufficient period to fully conclude remediation.
• The company is involved in a shareholder class action and derivative complaints alleging material misstatements or omissions in its IPO registration statement.

Risks

• Limited operating history, substantial net losses, and no products approved for commercial sale, with no guarantee of future profitability.
• Requires substantial additional capital to finance operations; inability to raise capital could force delays or elimination of development programs.
• Business depends entirely on the success of product candidates, which may not complete development, receive regulatory approval, or be successfully commercialized.
• Results from investigator-initiated trials or named patient use are not representative of clinical trial performance and cannot be used for regulatory approval.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting, affecting investor confidence.
• Difficulties in managing organizational growth and expanding operations, or loss of key personnel, could adversely affect the business.
• Preclinical and clinical development is lengthy, expensive, and uncertain, with earlier results not predictive of future trial outcomes.
• Difficulties enrolling patients in clinical trials could delay or adversely affect development activities.
• Significant competition from large and specialty pharmaceutical and biotechnology companies, some with approved therapies in target indications.
• Use of product candidates could be associated with side effects, adverse events, or safety risks, potentially leading to trial suspension, abandonment, delayed approval, or limited market acceptance.
• Reliance on third parties (CROs, CMOs, clinical sites) to conduct studies and trials, with risks of non-performance, regulatory non-compliance, missed deadlines, or relationship termination.
• Reliance on third-party manufacturers and suppliers, with risks of loss, failure to comply with regulations, or insufficient supply.
• Dependence on intellectual property licensed from third parties; termination of licenses could result in loss of significant rights.
• Inability to obtain and maintain sufficient intellectual property protection could allow competitors to commercialize similar products.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; failure to obtain approval would substantially harm the business.
• FDA investigation into T-cell malignancy risk following CAR T-cell immunotherapies (like KYV-101) may impact review, delay approvals, or require boxed warnings.
• Covenants and provisions in the Oxford Finance Loan and Security Agreement may restrict business operations and require maintaining certain liquidity levels, with default potentially leading to acceleration of repayment obligations and foreclosure on assets.
• Significant product liability risk inherent in development, testing, manufacturing, and marketing of new treatments, potentially leading to claims exceeding insurance coverage.
• Employees, contractors, and partners may engage in misconduct, including noncompliance with regulatory standards, leading to sanctions or lawsuits.
• Inability to use net operating loss (NOL) carryforwards and other tax attributes due to ownership changes (Section 382) or state limitations.
• Recent and future changes to tax laws (e.g., One Big Beautiful Bill Act, IRA) could materially adversely affect the company.
• Operations concentrated in one location, vulnerable to natural disasters or other unplanned events.
• Increasing use of social media platforms presents new risks and challenges, including noncompliance with adverse event reporting or inappropriate disclosures.
• Unfavorable global economic conditions, including macroeconomic conditions or geopolitical events, could adversely affect business.
• Subject to securities litigation, including a current class action and derivative complaints, which are expensive and divert management attention.
• Conducting clinical trials abroad carries additional risks, and foreign data may not be accepted by the FDA.
• Manufacturing process subject to FDA approval; failure by CMOs to meet requirements could impact development and approval.
• Dependence on limited source suppliers for critical materials; supply interruptions could delay development.
• Future collaborations may not be successful, or existing ones may terminate, impacting development and commercialization plans.
• Stock price volatility due to various factors, including clinical trial results, competitor announcements, and financing efforts.
• Market opportunities and forecasts may be inaccurate, leading to smaller actual markets.
• Future issuance of equity or convertible debt would dilute share capital.
• Anti-takeover provisions in charter documents and Delaware law could prevent or delay acquisitions.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Lack of analyst coverage or unfavorable research could cause stock price decline.
• Techniques employed by short sellers may drive down the market price.
• Artificial intelligence presents risks, including security risks to confidential information and an uncertain regulatory environment.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows to support product candidate development and research activities. With recent funding, existing cash and equivalents are estimated to fund operations into 2027, supporting the BLA filing for SPS and the registrational Phase 3 trial for MG, while accelerating pre-launch activities. Expenses are expected to increase substantially with continued clinical trials, pipeline expansion, manufacturing procurement, personnel growth, regulatory pursuits, and commercialization efforts. Profitability is not expected for the foreseeable future and depends on successful development, approval, and commercialization of product candidates.

Management Comments

• Management estimates that existing cash and cash equivalents and available-for-sale marketable securities balances will be sufficient to fund the operating plan and capital expenditure requirements for at least the next 12 months from the issuance of these condensed financial statements.
• With the initial $25.0 million of funding under the loan and security agreement entered into with Oxford Finance LLC in October 2025, we anticipate that our current cash, cash equivalents and available-for-sale marketable securities will be sufficient to fund our operations into 2027.
• We expect that our cash, cash equivalents and available-for-sale marketable securities will allow us to support our BLA filing for SPS and our registrational Phase 3 trial for MG, while accelerating our pre-launch activities.
• We believe we have good and substantial defenses to the claims in the Amended Complaint and the Derivative Actions, but there is no guarantee that we will be successful in these efforts.
• Our management is committed to continuing to make efforts to address each of the identified material weaknesses and believes the measures described above and upon completion of further operation and testing of the required controls will remediate the remaining material weaknesses and strengthen our internal control over financial reporting.

Industry Context

Kyverna Therapeutics operates in the highly competitive clinical-stage biopharmaceutical industry, specifically focusing on cell therapies for autoimmune diseases. The company's lead candidate, KYV-101, targets neuroimmunology and rheumatology, areas with existing approved treatments like Rituxan and Ocrevus, and numerous emerging therapies. The FDA's ongoing investigation into T-cell malignancy risk for CAR T-cell immunotherapies, including CD19-directed therapies like KYV-101, introduces a significant industry-wide regulatory challenge that could impact development timelines and approval conditions. The increasing focus on cost-containment measures and healthcare reform, such as the IRA and the recently enacted One Big Beautiful Bill Act, also creates a challenging pricing and reimbursement environment for novel therapies.

Comparison to Industry Standards

• KYV-101's underlying CAR, licensed from the NIH, completed a 20-patient Phase 1 oncology trial, reporting similar rates of durable antitumor responses with improved tolerability compared to the CAR used to create Yescarta. This suggests a potentially differentiated therapeutic profile for KYV-101 in autoimmune disease.
• The company faces competition from established therapies like Rituxan and Ocrevus (Roche Holding AG) and generic immunosuppressives, as well as other CAR T-cell candidates in development for B-cell-driven autoimmune diseases.
• The FDA's class safety labeling changes for BCMAor CD19-directed CAR T-cell immunotherapies, including a boxed warning for T-cell malignancies, sets a new safety standard for this class of therapies, which KYV-101 will need to navigate.

Corporate Governance

Legal Proceedings

• Shareholder class action complaint filed on December 9, 2024, alleging material misstatements or omissions in the IPO registration statement on Form S-1. An amended complaint was filed on May 2, 2025. Defendants filed a motion to dismiss on June 26, 2025.
• Stockholder derivative complaints (Perez Action and McDaniel Action) filed on May 14, 2025, and May 22, 2025, respectively, against current and former officers and directors, alleging claims related to the class action. These actions were consolidated and stayed pending the disposition of the motion to dismiss the class action.
• The company believes it has good and substantial defenses but is unable to estimate the range of potential loss, and no amount has been accrued in the financial statements.

Related Party Transactions

• In January 2020, the company entered into a License Agreement (Kite Agreement) with Kite Pharma, Inc., an affiliate of Gilead Sciences, Inc., a related party.
• The company was obligated to pay a $6.3 million sublicensing fee under the UCSF License Agreement, which was to be offset by future milestone payments from Gilead under a Collaboration, Option and License Agreement (Gilead Agreement).
• The Gilead Agreement terminated effective January 22, 2024, meaning no future milestones are payable to offset the sublicensing fee.
• As of September 30, 2025, the total sublicensing fee of $6.3 million was recorded as current accrued license expense related party.
• On October 24, 2025, the company, Kite, and Gilead entered into a letter agreement: the company agreed to pay $2.5 million in cash within 30 days and the remaining $3.8 million by December 31, 2026 (via equity, cash, or combination). The Kite Agreement was terminated, and parties mutually released from further obligations (except certain surviving provisions).
• In January 2024, a $1.1 million promissory note and accrued interest from the former CEO (a then-related party) related to early exercised options was forgiven. This was recognized as stock-based compensation expense.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises (shelf registration, ATM facility, equity incentive plans). Stock price volatility is a risk. Ongoing litigation could result in significant costs and reputational harm.
• Patients: Continued development of KYV-101 and KYV-102 offers potential new cell therapies for autoimmune diseases like SPS, MG, and LN. However, clinical trial delays or safety concerns (e.g., T-cell malignancy risk) could impact access to these treatments.
• Employees: Growth in the organization is expected, requiring additional personnel. Stock-based compensation plans are in place. Loss of key management or scientific personnel is a risk.
• Creditors: The new $150.0 million loan facility with Oxford Finance adds debt obligations and imposes covenants that could restrict business activities. Default could lead to foreclosure on assets.
• Regulatory Bodies: The company is subject to ongoing scrutiny from the FDA and other regulatory authorities, particularly regarding CAR T-cell therapy safety and manufacturing compliance.

Next Steps

• Report top-line data from the Phase 2 trial in Stiff Person Syndrome (SPS) in early 2026.
• Initiate patient enrollment in the Phase 3 portion of the Myasthenia Gravis (MG) trial by the end of 2025.
• Share updated data on the Phase 2 portion of the MG trial in 2026.
• File an Investigational New Drug (IND) application for KYV-102 in the fourth quarter of 2025.
• File a Biologics License Application (BLA) for SPS with the FDA in the first half of 2026.
• Share data from KYSA-1 and KYSA-3 Phase 1 trials for Lupus Nephritis (LN) in a peer-reviewed publication in 2026.
• Continue efforts to address and remediate identified material weaknesses in internal control over financial reporting.
• Pay $2.5 million in cash to Kite Pharma within 30 days of October 24, 2025, and the remaining $3.8 million by December 31, 2026.
• Monitor the effectiveness of remediation measures for internal controls.
• Evaluate the impact of new accounting standards (ASU No. 2023-09, ASU No. 2024-03, ASU No. 2025-06) on financial statements.

Key Dates

Recommendation

Kyverna Therapeutics shows promising clinical progress with its lead candidate KYV-101, particularly with completed enrollment for SPS Phase 2 and positive interim data for MG, along with RMAT and Orphan Drug designations. The recent non-dilutive financing from Oxford Finance provides a longer cash runway into 2027, which is crucial for continued development. However, the company faces substantial financial challenges, including increasing net losses, significant cash burn, and an accumulated deficit. The persistence of material weaknesses in internal controls and ongoing shareholder litigation introduce considerable operational and reputational risks. The broader regulatory scrutiny on CAR T-cell therapies also adds uncertainty. Given the early stage of commercialization, high burn rate, and existing risks, a 'hold' recommendation is appropriate. Investors should monitor the remediation of internal control weaknesses, the outcomes of legal proceedings, and the top-line data from upcoming clinical trials, especially for SPS and MG, as these will be critical determinants of future value.

Keywords

Kyverna Therapeutics, KYTX, Cell Therapy, Autoimmune Diseases, KYV-101, Stiff Person Syndrome, Myasthenia Gravis, Lupus Nephritis, Neuroimmunology, Rheumatology, Clinical Trials, Biopharmaceutical, CAR T-cell, SEC Filing, 10-Q, Financial Results, Biologics License Application, RMAT Designation, Orphan Drug Designation, Oxford Finance, Capital Raise, Internal Controls, Litigation, Research and Development